An adapted F-test for homogeneity of variability in follow-on biological products.
暂无分享,去创建一个
[1] S. Roger. Biosimilars: How similar or dissimilar are they? (Review Article) , 2006 .
[2] S. Chow,et al. Statistical Assessment of Biosimilar Products , 2009, Journal of biopharmaceutical statistics.
[3] Shein-Chung Chow,et al. Design and Analysis of Bioavailability and Bioequivalence Studies , 1994 .
[4] Shein-Chung Chow,et al. Statistical Test for Evaluation of Biosimilarity in Variability of Follow-On Biologics , 2010, Journal of biopharmaceutical statistics.
[5] S. Chow. Individual Bioequivalence—A Review of the FDA Draft Guidance , 1999 .
[6] S. Chow,et al. Design and Analysis of Bioavailability and Bioequivalence Studies, The Third Edition , 2008 .
[7] S. Roger. Biosimilars: how similar or dissimilar are they? , 2006, Nephrology.
[8] E. Chi,et al. A Comparison of Moment-Based and Probability-Based Criteria for Assessment of Follow-On Biologics , 2009, Journal of biopharmaceutical statistics.
[9] Steven Kozlowski,et al. The FDA's assessment of follow-on protein products: a historical perspective , 2007, Nature Reviews Drug Discovery.
[10] S. Roger,et al. Biosimilars: opportunity or cause for concern? , 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[11] Andrew R Fox. Biosimilar Medicines—New Challenges for a New Class of Medicine , 2009, Journal of biopharmaceutical statistics.